6533b823fe1ef96bd127e3ad

RESEARCH PRODUCT

COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis

Francesco DieliFrancesco SessaSebastiano Fabio GarozzoMonica SalernoAntonino GiarratanoClaudio TripodoDaniele Prati Pier Mannuccio MannucciMarcello CiaccioCristoforo PomaraMassimiliano EspositoGiovanni M. GiammancoPaolo ZamboniFrancesca Rappa

subject

Medicine (General)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical BiochemistryPopulation030204 cardiovascular system & hematologyArticledeep vein thrombosisAutoimmune thrombocytopenia03 medical and health sciencesautopsyR5-9200302 clinical medicinevaccinestandard protocolMedicineIntensive care medicineeducationAdverse effectdisseminated intravascular coagulationeducation.field_of_studySARS-CoV-2business.industryCOVID-19post-mortem investigationCausalityVaccinationimmune thrombocytopeniaImmunization030220 oncology & carcinogenesisvaccination campaignbusiness

description

The current challenge worldwide is the administration of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. Even if rarely, severe vascular adverse reactions temporally related to vaccine administration have induced diffidence in the population at large. In particular, researchers worldwide are focusing on the so-called “thrombosis and thrombocytopenia after COVID-19 vaccination”. This study aims to establish a practical workflow to define the relationship between adverse events following immunization (AEFI) and COVID-19 vaccination, following the basic framework of the World Health Organization (WHO). Post-mortem investigation plays a pivotal role to support this causality relationship when death occurs. To demonstrate the usefulness and feasibility of the proposed workflow, we applied it to two exemplificative cases of suspected AEFI following COVID-19 vaccination. Based on the proposed model, we took into consideration any possible causality relationship between COVID-19 vaccine administration and AEFI. This led us to conclude that vaccination with ChAdOx1 nCov-19 may cause the rare development of immune thrombocytopenia mediated by platelet-activating antibodies against platelet factor 4 (PF4), which clinically mimics heparin-induced autoimmune thrombocytopenia. We suggest the adoption of the proposed methodology in order to confirm or rule out a causal relationship between vaccination and the occurrence of AEFI.

https://doi.org/10.3390/diagnostics11060955